End-of-day quote Shanghai Stock Exchange 06:00:00 2023-09-21 pm EDT |
|
5-day change | 1st Jan Change | |
79.55 CNY | +1.27% | +2.04% | -1.79% |
Aug. 01 | WuXi AppTec Shares Rise After First-Half Earnings Beat | DJ |
Aug. 01 | WuXi AppTec's H1 Profit Rises 14.6% on Higher Revenue; Hong Kong Shares Rise 6% | MT |
Sales 2023 * | 41,934 M 5,745 M | Sales 2024 * | 52,785 M 7,232 M | Capitalization | 233 B 31 899 M |
---|---|---|---|---|---|
Net income 2023 * | 9,904 M 1,357 M | Net income 2024 * | 12,252 M 1,679 M | EV / Sales 2023 * | 5,44x |
Net cash position 2023 * | 4,628 M 634 M | Net cash position 2024 * | 7,428 M 1,018 M | EV / Sales 2024 * | 4,27x |
P/E ratio 2023 * | 23,7x | P/E ratio 2024 * | 19,1x | Employees | - |
Yield 2023 * | 1,14% | Yield 2024 * | 1,40% | Free-Float | 65.84% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | -2.05% | ||
1 week | +0.76% | ||
Current month | -3.62% | ||
1 month | +0.96% | ||
3 months | +24.09% | ||
6 months | -2.13% | ||
Current year | -3.02% |
1 week
78.28
81.62

1 month
75.54
83.45

Current year
61.24
100.00

1 year
61.24
100.00

3 years
61.24
172.49

5 years
29.97
172.49

10 years
11.02
172.49

Managers | Title | Age | Since |
---|---|---|---|
Ge Li
CEO | Chief Executive Officer | 56 | Jun. 05 |
Zhao Hui Zhang
PRN | Corporate Officer/Principal | 53 | Jun. 05 |
Qing Yang
CEO | Chief Executive Officer | 54 | 2020 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ge Li
CHM | Chairman | 56 | 2000 |
Qing Yang
BRD | Director/Board Member | 54 | 2020 |
Edward Hu
BRD | Director/Board Member | 60 | 2016 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.56% | 3 M$ | -17.58% | - |
Date | Price | Change | Volume |
---|---|---|---|
23-09-21 | 79.55 | +1.27% | 13 698 330 |
23-09-21 | 78.55 | -2.05% | 13,203,350 |
23-09-20 | 80.19 | -0.26% | 9,148,741 |
23-09-19 | 80.40 | -0.74% | 9,143,283 |
23-09-18 | 81.00 | +1.50% | 16,799,100 |
End-of-day quote Shanghai Stock Exchange, September 20, 2023
More quotes
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows:
- laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.;
- CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.;
- clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.;
- other (0.1%).
Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
Calendar
2023-11-01
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
A-
Sell
Buy

Mean consensus
BUY
Number of Analysts
27
Last Close Price
78.55CNY
Average target price
115.24CNY
Spread / Average Target
+46.71%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
-3.02% | 31 863 M $ | |
+36.89% | 29 562 M $ | |
-29.15% | 25 519 M $ | |
-13.29% | 23 838 M $ | |
-14.62% | 19 914 M $ | |
+27.28% | 11 583 M $ | |
-7.74% | 11 151 M $ | |
-5.30% | 11 045 M $ | |
+34.54% | 6 871 M $ | |
+353.20% | 6 559 M $ |